Kornimate/medical-research-clean huggingface dataset:
effect of vibration therapy on bone in persons with sub-acute spinal cord injury

Conditions: Spinal Cord Injuries

Summary: the purpose of this research study is to determine the effect of mechanical vibrations on bones of persons with spinal cord injury.

one of the major complications in persons with spinal cord injury (sci) is marked bone loss because it greatly predisposes to skeletal fractures, even after minimal trauma. the use of low magnitude mechanical stimulation has been shown to be both safe and effective in improving bone mass and strength in animal studies. this modality has also been shown a beneficial effect in children with disability and in postmenopausal women. the investigators are interested in obtaining data to determine the possible benefits that mechanical intervention with vibratory stimulation may have on bone in individuals with subacute sci (e.g., \>1 month after injury but \<1 year). changes in bone density and mass of the leg and arm will be determined by dual energy x-ray absorptiometry (dxa); bone architecture of the distal leg and distal arm will be determined by peripheral quantitative computed tomography; circulating metabolic markers of bone will also be performed. objectives in persons with subacute spinal cord injury: 1. to determine differences in bone mineral mass and parameters of bone structural integrity of the stimulated tibia versus the unstimulated tibia. 2. to determine changes in the metabolic markers of bone resorption and formation in persons with subacute spinal cord injury.

Eligibility criteria:
inclusion criteria: 1. males; 2. age 18-65; 3. non-ambulatory sci, with asia level a or b (asia a or b at the time of enrollment); 4. neurological level of injury c3-t10; 5. duration of injury \>1 month after injury but \<1 year; and 6.25(oh)d levels 30ng/ml (patients with values \<30ng/ml will be supplemented with vitamin d to normalize values prior to study participation). exclusion criteria: 1. osteoporosis or low bone mass as determined by medical history or dxa at the baseline visit; 2. pressure ulcer that may be exacerbated by the experimental procedure; 3. fracture of the lower extremity within the past 5 years; 4. active heterotopic ossification (ho); 5. history of metabolic bone disease; 6. knee replacement(s); 7. metal hardware in the lower extremities; 8. bisphosphonate administration; 9. severe underlying chronic illness (cardiac, pulmonary, gastrointestinal, etc.); 10. renal disease (creatinine clearance \< 40 ml/min); 11. 25(oh)d levels \<30ng/ml; 12. endocrine disorders known to be associated with osteoporosis (hyperthyroidism, hypercortisolism, and/or hypogonadism); 13. alcoholism; 14. seizure disorders; 15. history of kidney stones; and 16. compliance 85% for every month up to the 4-month time-point

Keywords: spinal cord injuries mechanical stimulation vibration plate
biodistribution, dosimetry and performance of [68ga]ga-dota-siglec-9 in healthy and patients with rheumatoid arthritis, vasculitis or pulmonary sarcoidosis

Conditions: Healthy Subjects; Rheumatoid Arthritis; Vasculitis; Pulmonary Sarcoidosis

Summary: this study evaluates safety, tolerability, biodistribution and performance of the \[68ga\]ga-dota-siglec-9 following a single intravenous administration in patients with active rheumatoid arthritis, vasculitis or pulmonary sarcoidosis as well as radiation dosimetry, plasma pharmacokinetics, biodistribution, safety and tolerability of the tracer in healthy volunteers.

vascular adhesion protein 1 (vap-1) is an inflammation inducible endothelial cell molecule mediating leukocyte trafficking from blood into the sites of inflammation. although vap-1 plays important role in early phases of inflammation, its luminal expression on the endothelium will remain constant if the inflammation continues, which suggest vap-1 as a promising target for molecular imaging of inflammation. we have previously shown that sialic acid-binding immunoglobulin-like lectin 9 (siglec-9) is a vap-1 ligand, and the gallium-68 labeled 1,4,7,10-tetraazacyclododecane-n,n´,n´´,n´´´-tetraacetic acid conjugated peptide (\[68ga\]ga-dota-siglec-9) containing residues 283-297 from siglec-9 can be used for pet imaging of inflammation in various experimental models. this first-in-human study evaluates safety, tolerability, biodistribution and performance of \[68ga\]ga-dota-siglec-9 after single intravenous injection in six healthy volunteers, and in ten patients with active rheumatoid arthritis (ra), five patients with vasculitis and five patients with pulmonary sarcoidosis.

Eligibility criteria:
inclusion criteria: * healthy 18-70 year-old men * male or female 18-70 year-old patients with active rheumatoid arthritis, vasculitis or pulmonary sarcoidosis exclusion criteria: * in healthy: ongoing infection/inflammation proven by blood or other tests * in patients with rheumatoid arthritis: no treatment with disease-modifying anti-rheumatic drugs or biologic agents, and no corticosteroids for 2 weeks prior the study * in patients with vasculitis: no immunosuppressives, and glucocorticoid less than 60 mg for 2 weeks or nsaids for 1 day prior the study * in patients with pulmonary sarcoidosis: no corticosteroids for 1 week or nsaids for day prior the study
shared care follow-up after chemotherapy for testicular cancer

Conditions: Testicular Cancer

Summary: the aim of this study is to develop and evaluate a shared care survivorship care plan (scp) to follow-up patients with metastatic testicular cancer after completion of chemotherapy that resulted in complete remission.

rationale: since the introduction of cisplatin, metastatic testicular cancer (tc) has become a highly curable disease. successfully treated tc patients have a small chance of a relapse. in case of a relapse, early treatment will improve outcome. this stresses the need for a frequent and stringent follow-up scheme. although chemotherapy is a very effective treatment, a downside of this treatment has now become apparent: chemotherapy-related complications such as the increased risk for cardiovascular disease (cvd) and secondary malignancies. cvd can manifest during treatment, but also years or decades thereafter. we recently observed early development of cardiovascular risk factors in tc patients, clustered into the metabolic syndrome. monitoring and treatment of cardiovascular risk factors during follow-up is important to lower the chance of developing cvd. since tc survivors are discharged from follow-up after 10 years, collaboration between oncologists and general practitioners (gps), in other words shared care, will ensure monitoring of cardiovascular risk factors and timely detection and treatment of late effects (cardiovascular risk management). survivorship care plans for cancer survivors, gps and oncologists facilitate care for long-term survivors. the testicular cancer survivor himself is the key person, who can be empowered to participate in follow-up programs and make lifestyle adjustments to decrease the risk of late effects and improve quality of life and life expectancy. however, data are scarce on the design of an evidence based effective follow-up schedule. for childhood cancer survivors a detailed guideline has been developed that can serve as a framework for adult cancer survivor follow-up. objective: to examine the safety and feasibility of a shared care survivorship care plan (scp) to follow-up patients with metastatic testicular cancer after completion of chemotherapy that resulted in complete remission. study population: patients that achieved a complete remission after chemotherapy for metastatic testicular cancer who are starting with follow-up or are currently in active follow-up.

Eligibility criteria:
inclusion criteria: * patients with disseminated testicular cancer; * complete remission after chemotherapy with or without adjunctive surgery and in active follow-up; * age 18 years or older; * started with chemotherapy after january 1st 2003; * written informed consent. exclusion criteria: •mental disability

Keywords: survivorship care testicular cancer shared care model
dependence receptors and leukemia

Conditions: Acute Lymphoblastic Leukemia; Acute Leukemia

Summary: acute leukaemias (al) are the first cause of cancer in children, with a majority of b acute lymphoblastic leukemia (all). some of the processes causing leukemogenesis are already identified and well characterized in some al subtypes such as translocation t (12; 21) of good prognosis in all. however, translocations are not sufficient to explain all the different processes of leukemogenesis, and other processes such as genetic / epigenetic mutations leading to oncogene activation / inhibition of tumor suppressor genes are the object research. among the latter, mutations in tumor suppressor genes such as dcc (deleted in colorectal cancer) have recently been identified in solid cancers, such as in hemopathies. this gene was subsequently characterized as encoding a "dependence receptor" specifically binding to its netrin-1 ligand. dependence receptors (rds) are transmembrane receptors that cause cell death in the absence of their ligand. rd decreases tumor progression and overexpression of their ligands is observed in many cancers, such as b lymphomatous hemopathies in adults. inhibition of the rd-ligand interaction constitutes a new and original therapeutic target in oncology. the aim of this study is to investigate whether rds, in particular dcc, are expressed in acute leukemia cells at the time of diagnosis or relapse in patients aged 1 to 18 years, and then in these patients at the time of the remission balance. this research will be both qualitative and quantitative.


Eligibility criteria:
inclusion criteria: * aged between 1 and 18 years * taken care of at the institute of hematology and pediatric oncology (service of professor yves bertrand, ihope) * for acute lymphoblastic or myeloblastic leukemia * initial diagnosis or relapse * who do not have a vital emergency criterion at the time of taking care (see exclusion criteria) * affiliated to a social security scheme (100% assumed) * after signing the informed consent of the holders of parental authority exclusion criteria: * less than 1 year, or more than 18 years to diagnosis * with chronic leukemia * severe anemia at diagnosis (hemoglobin \<40g / l), or a state of shock whatever the cause (infectious, cardiogenic, hypovolemic)
minimal and brief treatments for pathological gamblers

Conditions: Pathological Gambling

Summary: the purpose of the study is to examine whether problem gamblers who receive therapy calls in addition to a self-help manual will be more likely to quit or cut back on their gambling when compared with problem gamblers who receive just the manual.

with gambling becoming more accessible, the occurrence of problems related to gambling are on the rise. the costs of problem gambling are enormous.there are social and economic costs, the gambler can sometimes lose a significant relationship, job, or commit an illegal activity. pathological gamblers are also at risk for developing a general medical condition related to stress. there is a high risk of suicide and problem gamblers also have increased rates of mental health disorders. relatively few people choose to attend formal treatment programs so it's important to provide a range of options to make treatment more accessible. the present study examines the effectiveness of minimal and brief interventions delivered by the telephone. comparison(s): the "workbook only control" condition involves receiving the self-help booklet through the mail after a brief telephone assessment. the "minimal treatment" condition involves receiving the same workbook but also having a motivational enhancement intervention by telephone. the "brief treatment" condition provides the workbook, motivational enhancement, and follow-up support on six occasions spread over 36 weeks. the "wait list control" condition involves participants being assigned to a six week waiting list. participants are assessed and after a six week waiting period they will have a reassessment at which time they will be sent the gambling self-help workbook.

Eligibility criteria:
inclusion criteria: * over age 17 * perception of a gambling problem and a score of 3 or higher (moderate risk) on the canadian problem gambling index. * not involved in treatment at present. * willingness to read a short book written in english as a major treatment. * willing to have telephone contacts recorded. * willing to provide follow-up data on gambling. * willing to provide the name of a collateral to help locate them for follow-up interviews. * must have gambled at least once in the past month exclusion criteria: * participants in the preliminary study will be excluded.

Keywords: problem gambling self-help manual motivation enhancement telephone support treatment pathological gambling
strength training and executive functions: a randomized controlled trial

Conditions: Executive Function Disorder; Strength Training; Adolescent Behavior; Academic Achievement

Summary: a group of 50 age-schooled adolescents was randomized into one intervention and another control group of 25 subjects each. after estimating one maximum repetition for all the participants in a previous session, the intervention group performed a resistance training based on a resistance exercise of 3 sets of 3 to 5 repetitions (90% of an estimated 1 rm) whereas the control group performed both stretching and balance exercises. measures of executive functions ( i.e. a cognitive function associated with academic performance) were taken for all the participants before and after the training. both independent and paired t-test will serve to check differences between and within groups respectively.

a group of 50 age-schooled adolescents was randomized into one intervention and another control group of 25 subjects each. after estimating one maximum repetition for all the participants in a previous session, the intervention group performed a resistance training based on a resistance exercise of 3 sets of 3 to 5 repetitions (90% of an estimated 1 rm) whereas the control group performed both stretching and balance exercises. measures of executive functions ( i.e. a cognitive function associated with academic performance) were taken for all the participants before and after the training. both independent and paired t-test will serve to check differences between and within groups respectively. the selected resistance exercise is based on a global muscle involvement.

Eligibility criteria:
inclusion criteria: * healthy age-schooled adolescent exclusion criteria: * not healthy, injured age-schooled adolescent
effect of negative pressure wound therapy for soft tissue injuries of foot and ankle in patients at a tertiary care hospital

Conditions: Soft Tissue Injuries

Summary: effect of negative pressure wound therapy for soft tissue iinjuries of foot and ankle in patients at a tertiary care hospital. to evaluate the effect of negative pressure wound therapy for soft tissue injuries of foot and ankle.this will be assessed through measuring the wound surface area covered with healthy granulation tissue measured in centimetre square on follow-up.

all patients aged 18 years or above with foot and ankle trauma resulting in soft tissue injury with or without bones and tendon exposed were included in the study. 35 patients were randomized into negative pressure wound therapy group and 35 in conventional treatment group.in npwt group ,npwt was applied to injured area of foot and ankle after debridement and cleaning of the necrosed/dead tissue. the effect of technique was assessed through measuring wound surface area covered with healthy granulation tissue measured in centimetre square on follow-up at 10 days ,20 days and 27 days respectively. in conventional treatment group patients were kept on simple moist gauze dressings and the wound was assessed through measuring wound surface area covered with healthy granulation tissue measured in centimeter square on followup at 10 days , 20 days and 27 days respectively.

Eligibility criteria:
inclusion criteria: 1. all patients aged 18 years or above with foot and ankle trauma resulting in soft tissue injury with bones and tendon exposed 2. patients consenting to participate in the study exclusion criteria: 1. patients with uncontrolled diabetes mellitus 2. patients with multiple fractures
cord clamping level above or below mother's perineum

Conditions: Pre-term Birth; Delayed Cord Clamping

Summary: the purpose of this study is to determine if delayed cord clamping above the perineum has an effect on neonatal hematocrit when compared to delayed cord clamping below the perineum in pre-term spontaneous vaginal deliveries.

this study will compare the difference in neonatal hematocrit with delayed cord clamping above vs. below the perineum, in infants who are born via pre-term spontaneous vaginal deliveries that are vigorous at delivery. delayed cord clamping below the perineum is an accepted clinical practice in obstetrics and gynecology; however, delayed cord clamping above the perineum has not yet been studied in preterm infants. delayed cord clamping above the perineum will provide the benefit of immediate skin-to-skin contact between the mother and her newborn. patients will have delayed cord clamping performed for 60-75 seconds either below the maternal perineum or while the infant is placed on the mother's abdomen. at approximately 24 hours after delivery (at the time of infant heel stick for routine, state-mandated screening tests), a small additional amount of blood will be collected to evaluate newborn hematocrit.

Eligibility criteria:
inclusion criteria: * singleton intrauterine pregnancies at least 30 weeks gestation but less than 37 weeks gestation exclusion criteria: * acute febrile illnesses or chronic medical problems such as hypertension, diabetes mellitus, renal disease, medically-managed seizure disorders * pregnancy-related complications such as pre-eclampsia, intrauterine growth restriction, chromosomal/anatomical abnormalities, and placental abruption * infants who are not anticipated to undergo spontaneous vaginal delivery

Keywords: pre-term birth delayed cord clamping skin to skin
a clinical trial of the safety and anti-tumor activity of ab-201 in subjects with advanced her2+ solid tumors

Conditions: Breast Cancer; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma

Summary: this clinical trial will enroll subjects with her2+ solid tumors and is conducted in two phases. the primary objective of phase 1 is to determine the safety and tolerability of ab-201 in subjects with advanced her2+ solid tumors. the primary objective of phase 2 is to evaluate the efficacy of ab-201. subjects will receive up to 3 doses of ab-201, followed by scheduled assessments of overall health and tumor response.


Eligibility criteria:
inclusion criteria: * ecog performance status 0 to 1. * histologically confirmed her2 expressed breast or gastric/gej cancer ihc ≥ 2+ within 6 months prior to study entry. * confirmed diagnosis of an advanced/unresectable or metastatic her2+ breast or gastric/gej cancer that is refractory to, or intolerable of standard treatment, or for which no standard treatment is available. * must have received prior cancer therapy: subjects with breast cancer must have received ≥ 2 prior systemic therapies; subjects with gastric/gej cancer must have received ≥ 1 prior systemic therapy(ies); subjects with ihc 3+ or ihc 2+/ish+ cancers must have received previous treatment with a her2-targeting therapy. exclusion criteria: * known past or current malignancy other than inclusion diagnosis. * known clinically significant cardiac disease. * active central nervous system (cns) metastases, or involvement of the cns, unless there is a history of at least 3 months of sustained remission. * unresolved toxicities from prior anticancer therapy. * ongoing uncontrolled systemic infections requiring antibiotic, anti-fungal, or anti-viral therapy. * history of sensitivity or intolerance to cyclophosphamide or fludarabine. * pregnant or lactating females and subjects of both sexes who are not willing to practice birth control from the time of consent through 6 months after administration of the last ab-201 dose. * severe disease progression or health deterioration within 2 weeks prior to lymphodepletion regimen.
evaluation of step-based care for individuals at clinical high risk for psychosis

Conditions: Prodromal Schizophrenia

Summary: the ohio state university early psychosis intervention center is implementing a specialized clinical program to serve individuals who meet clinical high risk criteria for a psychosis. the purpose of this study is to evaluate the long-term outcomes among individuals participating in this clinical service.

the ohio state university early psychosis intervention center (osu epicenter) is implementing a specialized clinical program to serve individuals ages 12-25 who meet clinical high risk criteria for a psychosis (chr-p). the purpose of this project is to evaluate (i) correlates of baseline characteristics among clinic participants; (ii) outcomes among individuals participating in this clinical service; and (iii) predictors and mediators of longitudinal outcomes among individuals participating in this clinical service.

Eligibility criteria:
inclusion criteria: * male and female patients between ages 12-25 * individuals meeting clinical high-risk criteria for psychosis as determined using the structured interview for psychosis risk. inclusive of individuals meeting any of the three chr syndromes assessed by the sips (i.e., attenuated psychotic symptoms; brief intermittent psychosis, and genetic risk and functional deterioration) and/or individuals at all four current status specifiers for the sips (i.e., progression, persistence, partial remission, and full remission) given evidence that future worsening of symptoms and/or progression to psychosis is possible for individuals in each current status specifier category. * subjects with no evidence of a pre-existing intellectual disability defined as a premorbid iq \>70 as estimated using the reading subtest of the wide range achievement test-4 * fluent in english per self-report

Keywords: psychosis treatment clinical high-risk